Floatz logo

VINCRISTINE SULFATE

Unspecified Childhood Solid Tumor, Protocol Specific

Children's Oncology GroupSmall moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Unspecified Childhood Solid Tumor, Protocol Specific cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
City of Hope Medical Center
Phase 2/3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2/3BBB
FILGRASTIM
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Carboplatin
Seoul National University Hospital
Phase 2/3BBB
Busulphan
City of Hope Medical Center
Phase 2/3BBB

View all 50 →

Same molecule, other indications

VINCRISTINE SULFATE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
diffuse large B-cell lymphomaDormant
A
Indicative ·
80 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →